Fragment-based approaches and computer-aided drug discovery

Topics in Current Chemistry

Volumn 317, Issue , 2012, Pages 201-222

  Rognan, Didier ^a  

^a UNIVERSITÉ DE STRASBOURG   (France)

Author keywords

Docking; Drug design; Fragment; Library

Indexed keywords

LIGAND;

ARTICLE; CHEMICAL STRUCTURE; CHEMISTRY; COMPUTER AIDED DESIGN; DRUG DEVELOPMENT; MOLECULAR LIBRARY; X RAY CRYSTALLOGRAPHY;

COMPUTER-AIDED DESIGN; CRYSTALLOGRAPHY, X-RAY; DRUG DISCOVERY; LIGANDS; MODELS, MOLECULAR; SMALL MOLECULE LIBRARIES;

EID: 84858133674     PISSN: 03401022     EISSN: None     Source Type: Book Series    
DOI: 10.1007/128-2011-182     Document Type: Article

References (119)

1. Shuker SB, Hajduk PJ, Meadows RP et al (1996) Discovering high-affinity ligands for proteins: SAR by NMR. Science 274:1531-1534 (Pubitemid 26403929)
2. Kola I, Landis J (2004) Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 3:711-715 (Pubitemid 39173511)
3. Venter JC, Adams MD, Myers EW et al (2001) The sequence of the human genome. Science 291:1304-1351 (Pubitemid 32173090)
4. Schreiber SL (2000) Target-oriented and diversity-oriented organic synthesis in drug discovery. Science 287:1964-1969 (Pubitemid 30158663)
5. Pereira DA, Williams JA (2007) Origin and evolution of high throughput screening. Br J Pharmacol 152:53-61 (Pubitemid 47339909)
6. Lipinski CA, Lombardo F, Dominy BW et al (2001) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 46:3-26 (Pubitemid 33653411)
7. Hann MM, Leach AR, Harper G (2001) Molecular complexity and its impact on the probability of finding leads for drug discovery. J Chem Inf Comput Sci 41:856-864
8. Congreve M, Marshall F (2010) The impact of GPCR structures on pharmacology and structure-based drug design. Br J Pharmacol 159:986-996
9. Congreve M, Chessari G, Tisi D et al (2008) Recent developments in fragment-based drug discovery. J Med Chem 51:3661-3680 (Pubitemid 351956496)
10. MurrayCW, Rees DC (2009) The rise of fragment-based drug discovery. Nat Chem, 1:187-192
11. Orita M, Warizaya M, Amano Y et al (2009) Advances in fragment-based drug discovery platforms. Expert Opin Drug Discov 4:1125-1144
12. Warr WA (2009) Fragment-based drug discovery. J Comput Aided Mol Des 23:453-458
13. Erlanson DA (2006) Fragment-based lead discovery: a chemical update. Curr Opin Biotechnol 17:643-652 (Pubitemid 44791912)
14. Hajduk PJ, Greer J (2007) A decade of fragment-based drug design: strategic advances and lessons learned. Nat Rev Drug Discov 6:211-219 (Pubitemid 46344625)
15. Law R, Barker O, Barker JJ et al (2009) The multiple roles of computational chemistry in fragment-based drug design. J Comput Aided Mol Des 23:459-473
16. Jencks WP (1981) On the attribution and additivity of binding energies. Proc Natl Acad Sci USA 78:4046-4050 (Pubitemid 11010286)
17. Kuntz ID, Chen K, Sharp KA et al (1999) The maximal affinity of ligands. Proc Natl Acad Sci USA 96:9997-10002 (Pubitemid 29422500)
18. Hopkins AL, Groom CR, Alex A (2004) Ligand efficiency: a useful metric for lead selection. Drug Discov Today 9:430-431 (Pubitemid 38510559)
19. Reynolds CH, Bembenek SD, Tounge BA (2007) The role of molecular size in ligand efficiency. Bioorg Med Chem Lett 17:4258-4261 (Pubitemid 47028600)
20. Orita M, Ohno K, Niimi T (2009) Two 'Golden Ratio' indices in fragment-based drug discovery. Drug Discov Today 14:321-328
21. Abad-Zapatero C, Perisic O, Wass J et al (2010) Ligand efficiency indices for an effective mapping of chemico-biological space: the concept of an atlas-like representation. Drug Discov Today 15:804-811
22. Murray CW, Verdonk ML (2002) The consequences of translational and rotational entropy lost by small molecules on binding to proteins. J Comput Aided Mol Des 16:741-753 (Pubitemid 36336183)
23. Borsi V, Calderone V, Fragai M et al (2010) Entropic contribution to the linking coefficient in fragment based drug design: a case study. J Med Chem 53:4285-4289
24. Babaoglu K, Shoichet BK (2006) Deconstructing fragment-based inhibitor discovery. Nat Chem Biol 2:720-723 (Pubitemid 44764214)
25. Chung S, Parker JB, Bianchet M et al (2009) Impact of linker strain and flexibility in the design of a fragment-based inhibitor. Nat Chem Biol 5:407-413
26. Blum LC, Reymond JL (2009) 970 million druglike small molecules for virtual screening in the chemical universe database GDB-13. J Am Chem Soc 131:8732-8733
27. Siegal G, Ab E, Schultz J (2007) Integration of fragment screening and library design. Drug Discov Today 12:1032-1039 (Pubitemid 350180558)
28. Congreve M, Carr R, Murray C et al (2003) A 'rule of three' for fragment-based lead discovery? Drug Discov Today 8:876-877 (Pubitemid 37194496)
29. Baurin N, Aboul-Ela F, Barril X et al (2004) Design and characterization of libraries of molecular fragments for use in NMR screening against protein targets. J Chem Inf Comput Sci 44:2157-2166
30. Schuffenhauer A, Ruedisser S, Marzinzik AL et al (2005) Library design for fragment based screening. Curr Top Med Chem 5:751-762 (Pubitemid 41179715)
31. Venhorst J, Núñez S, Kruse CG (2010) Design of a high fragment efficiency library by molecular graph theory. ACS Med Chem Lett 1:499-503
32. Gianti E, Sartori L (2008) Identification and selection of "privileged fragments" suitable for primary screening. J Chem Inf Model 48:2129-2139
33. Lewell XQ, Judd DB, Watson SP et al (1998) RECAP-retrosynthetic combinatorial analysis procedure: a powerful new technique for identifying privileged molecular fragments with useful applications in combinatorial chemistry. J Chem Inf Comput Sci 38:511-522 (Pubitemid 128594467)
34. Maass P, Schulz-Gasch T, Stahl M et al (2007) Recore: a fast and versatile method for scaffold hopping based on small molecule crystal structure conformations. J Chem Inf Model 47:390-399 (Pubitemid 46615943)
35. Degen J, Wegscheid-Gerlach C, Zaliani A et al (2008) On the art of compiling and using 'drug-like' chemical fragment spaces. ChemMedChem 3:1503-1507
36. Mauser H, Stahl M (2007) Chemical fragment spaces for de novo design. J Chem Inf Model 47:318-324 (Pubitemid 46615936)
37. Lameijer EW, Kok JN, Back T et al (2006) Mining a chemical database for fragment cooccurrence: discovery of "chemical cliches". J Chem Inf Model 46:553-562
38. Hopkins AL, Groom CR (2002) The druggable genome. Nat Rev Drug Discov 1:727-730 (Pubitemid 37361545)
39. Hajduk PJ, Huth JR, Fesik SW (2005) Druggability indices for protein targets derived from NMR-based screening data. J Med Chem 48:2518-2525 (Pubitemid 40516441)
40. Ciulli A, Williams G, Smith AG et al (2006) Probing hot spots at protein-ligand binding sites: a fragment-based approach using biophysical methods. J Med Chem 49:4992-5000 (Pubitemid 44201057)
41. Mattos C, Ringe D (1996) Locating and characterizing binding sites on proteins. Nat Biotechnol 14:595-599 (Pubitemid 26135122)
42. Goodford PJ (1985) A computational procedure for determining energetically favorable binding sites on biologically important macromolecules. J Med Chem 28:849-857 (Pubitemid 15012490)
43. Rognan D, Scapozza L, Folkers G et al (1995) Rational design of nonnatural peptides as high-affinity ligands for the HLA-B*2705 human leukocyte antigen. Proc Natl Acad Sci USA 92:753-757
44. von Itzstein M, Dyason JC, Oliver SW et al (1996) A study of the active site of influenza virus sialidase: an approach to the rational design of novel anti-influenza drugs. J Med Chem 39:388-391 (Pubitemid 26037893)
45. Miranker A, Karplus M (1991) Functionality maps of binding sites: a multiple copy simultaneous search method. Proteins 11:29-34
46. Eisen MB, Wiley DC, Karplus M et al (1994) HOOK: a program for finding novel molecular architectures that satisfy the chemical and steric requirements of a macromolecule binding site. Proteins 19:199-221 (Pubitemid 24215048)
47. Schubert CR, Stultz CM (2009) The multi-copy simultaneous search methodology: a fundamental tool for structure-based drug design. J Comput Aided Mol Des 23:475-489
48. Bohm HJ (1992) The computer program LUDI: a new method for the de novo design of enzyme inhibitors. J Comput Aided Mol Des 6:61-78
49. Verdonk ML, Cole JC, Taylor R (1999) SuperStar: a knowledge-based approach for identifying interaction sites in proteins. J Mol Biol 289:1093-1108 (Pubitemid 29306672)
50. Dennis S, Kortvelyesi T, Vajda S (2002) Computational mapping identifies the binding sites of organic solvents on proteins. Proc Natl Acad Sci USA 99:4290-4295 (Pubitemid 34285978)
51. Brenke R, KozakovD,ChuangGYet al (2009) Fragment-based identification of druggable 'hot spots' of proteins using Fourier domain correlation techniques. Bioinformatics 25:621-627
52. Chuang GY, Kozakov D, Brenke R et al (2009) Binding hot spots and amantadine orientation in the influenza a virus M2 proton channel. Biophys J 97:2846-2853
53. Landon MR, Lieberman RL, Hoang QQ et al (2009) Detection of ligand binding hot spots on protein surfaces via fragment-based methods: application to DJ-1 and glucocerebrosidase. J Comput Aided Mol Des 23:491-500
54. Guvench O, MacKerell AD Jr (2009) Computational fragment-based binding site identification by ligand competitive saturation. PLoS Comput Biol 5:e1000435
55. Kasahara K, Kinoshita K, Takagi T (2010) Ligand-binding site prediction of proteins based on known fragment-fragment interactions. Bioinformatics 26:1493-1499
56. Huang N, Jacobson MP (2010) Binding-site assessment by virtual fragment screening. PLoS One 5:e10109
57. Irwin JJ, Shoichet BK (2005) ZINC-a free database of commercially available compounds for virtual screening. J Chem Inf Model 45:177-182 (Pubitemid 40736970)
58. Halgren TA (2009) Identifying and characterizing binding sites and assessing druggability. J Chem Inf Model 49:377-389
59. Schmidtke P, Barril X (2010) Understanding and predicting druggability. A high-throughput method for detection of drug binding sites. J Med Chem 53:5858-5867
60. Schneider G, Fechner U (2005) Computer-based de novo design of drug-like molecules. Nat Rev Drug Discov 4:649-663 (Pubitemid 41149759)
61. Loving K, Alberts I, Sherman W (2010) Computational approaches for fragment-based and de novo design. Curr Top Med Chem 10:14-32
62. Moitessier N, Englebienne P, Lee D et al (2008) Towards the development of universal, fast and highly accurate docking/scoringmethods: a long way to go. Br J Pharmacol 153(Suppl 1):S7-S26 (Pubitemid 351340987)
63. Kuntz ID, Blaney JM, Oatley SJ et al (1982) A geometric approach to macromolecule-ligand interactions. J Mol Biol 161:269-288
64. B-Rao C, Subramanian J, Sharma SD (2009) Managing protein flexibility in docking and its applications. Drug Discov Today 14:394-400
65. Rarey M, Kramer B, Lengauer T (1999) The particle concept: placing discrete water molecules during protein-ligand docking predictions. Proteins 34:17-28 (Pubitemid 29019529)
66. Klebe G, Mietzner T (1994) A fast and efficient method to generate biologically relevant conformations. J Comput Aided Mol Des 8:583-606
67. Sun Y, Ewing TJ, Skillman AG et al (1998) CombiDOCK: structure-based combinatorial docking and library design. J Comput Aided Mol Des 12:597-604 (Pubitemid 128512195)
68. Zsoldos Z, Reid D, Simon A et al (2007) eHiTS: a new fast, exhaustive flexible ligand docking system. J Mol Graph Model 26:198-212 (Pubitemid 46977244)
69. Huang D, Caflisch A (2010) Library screening by fragment-based docking. J Mol Recognit 23:183-193
70. Verdonk ML, Berdini V, Hartshorn MJ et al (2004) Virtual screening using protein-ligand docking: avoiding artificial enrichment. J Chem Inf Comput Sci 44:793-806
71. Marcou G, Rognan D (2007) Optimizing fragment and scaffold docking by use of molecular interaction fingerprints. J Chem Inf Model 47:195-207 (Pubitemid 46237537)
72. Li Y, Shen J, Sun X et al (2010) Accuracy assessment of protein-based docking programs against RNA targets. J Chem Inf Model 50:1134-1146
73. Verdonk ML, Cole JC, Hartshorn MJ et al (2003) Improved protein-ligand docking using GOLD. Proteins 52:609-623 (Pubitemid 37034158)
74. Friesner RA, Banks JL, Murphy RB et al (2004) Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J Med Chem 47:1739-1749 (Pubitemid 38380917)
75. Sandor M, Kiss R, Keseru GM (2010) Virtual fragment docking by Glide: a validation study on 190 protein-fragment complexes. J Chem Inf Model 50:1165-1172
76. Boehm HJ, Boehringer M, Bur D et al (2000) Novel inhibitors of DNA gyrase: 3D structure based biased needle screening, hit validation by biophysical methods, and 3D guided optimization. A promising alternative to random screening. J Med Chem 43:2664-2674 (Pubitemid 30463915)
77. Makino S, Kayahara T, Tashiro K et al (2001) Discovery of a novel serine protease inhibitor utilizing a structure-based and experimental selection of fragments technique. J Comput Aided Mol Des 15:553-559 (Pubitemid 32677164)
78. Pickett SD, Sherborne BS, Wilkinson T et al (2003) Discovery of novel low molecular weight inhibitors of IMPDH via virtual needle screening. Bioorg Med Chem Lett 13:1691-1694 (Pubitemid 36561143)
79. Carbone V, Ishikura S, Hara A et al (2005) Structure-based discovery of human L-xylulose reductase inhibitors from database screening and molecular docking. Bioorg Med Chem 13:301-312 (Pubitemid 39642914)
80. Warner SL, Bashyam S, Vankayalapati H et al (2006) Identification of a lead small-molecule inhibitor of the Aurora kinases using a structure-assisted, fragment-based approach. Mol Cancer Ther 5:1764-1773 (Pubitemid 44323244)
81. Rummey C, Nordhoff S, Thiemann M et al (2006) In silico fragment-based discovery of DPP-IV S1 pocket binders. Bioorg Med Chem Lett 16:1405-1409 (Pubitemid 43143031)
82. Teotico DG, Babaoglu K, Rocklin GJ et al (2009) Docking for fragment inhibitors of AmpC beta-lactamase. Proc Natl Acad Sci USA 106:7455-7460
83. Chen D, Misra M, Sower L et al (2008) Novel inhibitors of anthrax edema factor. Bioorg Med Chem 16:7225-7233
84. Chen Y, Shoichet BK (2009) Molecular docking and ligand specificity in fragment-based inhibitor discovery. Nat Chem Biol 5:358-364
85. McLean LR, Zhang Y, Li H et al (2010) Fragment screening of inhibitors for MIF tautomerase reveals a cryptic surface binding site. Bioorg Med Chem Lett 20:1821-1824
86. Englert L, Silber K, Steuber H et al (2010) Fragment-based lead discovery: screening and optimizing fragments for thermolysin inhibition. ChemMedChem 5:930-940
87. Ruda GF, Campbell G, Alibu VP et al (2010) Virtual fragment screening for novel inhibitors of 6-phosphogluconate dehydrogenase. Bioorg Med Chem 18:5056-5062
88. Rohrig UF, Awad L, Grosdidier A et al (2010) Rational design of indoleamine 2,3-dioxygenase inhibitors. J Med Chem 53:1172-1189
89. Mortier J, Masereel B, Remouchamps C et al (2010) NF-kappaB inducing kinase (NIK) inhibitors: identification of new scaffolds using virtual screening. Bioorg MedChem Lett 20:4515-4520
90. Gleeson MP, Gleeson D (2009) QM/MM as a tool in fragment based drug discovery. A crossdocking, rescoring study of kinase inhibitors. J Chem Inf Model 49:1437-1448
91. Graves AP, Shivakumar DM, Boyce SE et al (2008) Rescoring docking hit lists for model cavity sites: predictions and experimental testing. J Mol Biol 377:914-934
92. Novikov FN, Stroylov VS, Stroganov OV et al (2010) Improving performance of dockingbased virtual screening by structural filtration. J Mol Model 16:1223-1230
93. Deng Z, Chuaqui C, Singh J (2004) Structural interaction fingerprint (SIFt): a novel method for analyzing three-dimensional protein-ligand binding interactions. J Med Chem 47:337-344 (Pubitemid 38057878)
94. Kelly MD, Mancera RL (2004) Expanded interaction fingerprint method for analyzing ligand binding modes in docking and structure-based drug design. J Chem Inf Comput Sci 44:1942-1951
95. Mpamhanga CP, Chen B, McLay IM et al (2006) Knowledge-based interaction fingerprint scoring: a simple method for improving the effectiveness of fast scoring functions. J Chem Inf Model 46:686-698
96. Venhorst J, Nunez S, Terpstra JW et al (2008) Assessment of scaffold hopping efficiency by use of molecular interaction fingerprints. J Med Chem 51:3222-3229 (Pubitemid 351821881)
97. Loving K, Salam NK, Sherman W (2009) Energetic analysis of fragment docking and application to structure-based pharmacophore hypothesis generation. J Comput Aided Mol Des 23:541-554
98. Fukunishi Y, Mashimo T, Orita M et al (2009) In silico fragment screening by replica generation (FSRG) method for fragment-based drug design. J Chem Inf Model 49:925-933
99. Li H, Li C (2010) Multiple ligand simultaneous docking: orchestrated dancing of ligands in binding sites of protein. J Comput Chem 31:2014-2022
100. Babine RE, Bleckman TM, Kissinger CR et al (1995) Design, synthesis and X-ray crystallographic studies of novel FKBP-12 ligands. Bioorg Med Chem Lett 5:1719-1724
101. Rich DH, Bohacek RS, Dales NA et al (1997) Transformation of peptides into non-peptides. Synthesis of computer-generated enzyme inhibitors. Chimia 51:45-47
102. Bohm HJ, Banner DW, Weber L (1999) Combinatorial docking and combinatorial chemistry: design of potent non-peptide thrombin inhibitors. J Comput Aided Mol Des 13:51-56 (Pubitemid 29098942)
103. Honma T, Hayashi K, Aoyama T et al (2001) Structure-based generation of a new class of potent Cdk4 inhibitors: new de novo design strategy and library design. J Med Chem 44:4615-4627 (Pubitemid 33144471)
104. Schneider G, Lee ML, Stahl M et al (2000) De novo design of molecular architectures by evolutionary assembly of drug-derived building blocks. J Comput Aided Mol Des 14:487-494 (Pubitemid 30386823)
105. Grzybowski BA, Ishchenko AV, Kim CY et al (2002) Combinatorial computational method gives new picomolar ligands for a known enzyme. Proc Natl Acad Sci USA 99:1270-1273 (Pubitemid 34136482)
106. Ji H, Zhang W, Zhang M et al (2003) Structure-based de novo design, synthesis, and biological evaluation of non-azole inhibitors specific for lanosterol 14alpha-demethylase of fungi. J Med Chem 46:474-485 (Pubitemid 36182750)
107. Vinkers HM, de Jonge MR, Daeyaert FF et al (2003) SYNOPSIS: SYNthesize and OPtimize System in Silico. J Med Chem 46:2765-2773 (Pubitemid 36702544)
108. Rogers-Evans M, Alanine AI, Bleicher KH et al (2004) Identification of novel cannabinoid receptor ligands via evolutionary de novo design and rapid parallel synthesis. QSAR & Comb Sci 23:426-430 (Pubitemid 39490404)
109. Pierce AC, Rao G, Bemis GW (2004) BREED: Generating novel inhibitors through hybridization of known ligands. Application to CDK2, p38, and HIV protease. J Med Chem 47:2768-2775 (Pubitemid 38656730)
110. Krier M, Araujo-Junior JX, Schmitt M et al (2005) Design of small-sized libraries by combinatorial assembly of linkers and functional groups to a given scaffold: application to the structure-based optimization of a phosphodiesterase 4 inhibitor. J Med Chem 48:3816-3822 (Pubitemid 40776856)
111. Heikkila T, Thirumalairajan S, DaviesMet al (2006) The first de novo designed inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase. Bioorg Med Chem Lett 16:88-92 (Pubitemid 41625648)
112. Roche O, Rodriguez Sarmiento RM (2007) A new class of histamine H3 receptor antagonists derived from ligand based design. Bioorg Med Chem Lett 17:3670-3675 (Pubitemid 46898822)
113. Vieth M, Erickson J, Wang J et al (2009) Kinase inhibitor data modeling and de novo inhibitor design with fragment approaches. J Med Chem 52:6456-6466
114. Aronov AM, Bemis GW (2004) A minimalist approach to fragment-based ligand design using common rings and linkers: application to kinase inhibitors. Proteins 57:36-50 (Pubitemid 39195883)
115. Crisman TJ, Bender A, Milik M et al (2008) "Virtual fragment linking": an approach to identify potent binders from low affinity fragment hits. J Med Chem 51:2481-2491 (Pubitemid 351628509)
116. Willett P (2006) Similarity-based virtual screening using 2D fingerprints. Drug Discov Today 11:1046-1053 (Pubitemid 44792477)
117. Bender A, Mussa HY, Gill GS et al (2004) Molecular surface point environments for virtual screening and the elucidation of binding patterns (MOLPRINT 3D). J Med Chem 47:6569-6583 (Pubitemid 39662752)
118. Nidhi GM, Davies JW et al (2006) Prediction of biological targets for compounds using multiple-category Bayesian models trained on chemogenomics databases. J Chem Inf Model 46:1124-1133 (Pubitemid 43999157)
119. Clark M, Wiseman JS (2009) Fragment-based prediction of the clinical occurrence of long QT syndrome and torsade de pointes. J Chem Inf Model 49:2617-2626